An interventional study of 10-week web-based psychoeducational program in Functional Hypothalamic Amenorrhea, sponsored by Karolinska Institutet. Recruiting at 2 sites in Sweden. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a single-arm feasibility trial evaluating a 10-week web-based psychoeducational intervention for women with functional hypothalamic amenorrhea (FHA). The primary aim is to assess feasibility and acceptability prior to a future randomized controlled trial.
Intervention The intervention is delivered via a secure web-based platform over 10 weeks. Delivered via Inera's Stöd och behandling platform (1177) with BankID login; one module per week; no therapist support. It consists of sequentially released modules including psychoeducational content, reflective exercises, and practical strategies targeting factors relevant to FHA, including energy availability, stress regulation, recovery, nutrition, physical activity, and psychological well-being. The program is self-guided and designed for remote access. No therapist support is provided within the platform.
The intervention content has been developed through an iterative co-creation process involving clinicians (gynecology, psychology, physiotherapy, dietetics) and patient representatives.
Study procedures and setting Participants are recruited via clinical referral from gynecological outpatient services. All participants undergo baseline clinical assessment at the Gynecological Endocrinology Clinic at Karolinska University Hospital to confirm diagnosis of FHA prior to enrollment.
Assessments are conducted at baseline (T0), post-intervention at 10 weeks (T1), and follow-up at 4 and 8 weeks post-intervention (T2).
At baseline, diagnosis is confirmed through clinical evaluation, medical history, gynecological examination, and hormonal assessment consistent with hypogonadotropic hypogonadism. Psychiatric comorbidity is assessed using the DIAMOND Psychiatric Interview.
Self-report questionnaires are completed electronically via REDCap at T0, T1 and T2, assessing psychological and behavioral outcomes including perceived stress, coping, anxiety, depressive symptoms, eating-related behaviors, exercise patterns, and personality-related traits associated with FHA.
Outcomes Primary outcomes include feasibility and acceptability metrics: recruitment rate, retention, intervention completion, adherence to modules, and participant satisfaction.
Secondary outcome includes change in luteinizing hormone (LH) levels from baseline to post-intervention as a physiological marker of hypothalamic-pituitary-gonadal axis activity.
Exploratory outcomes include changes in psychological and behavioral measures from baseline to post-intervention and follow-up.
Statistical analysis Analyses are descriptive. Proportions are presented with exact 95% confidence intervals and changes from baseline with 95% confidence intervals; no formal hypothesis testing of effectiveness is planned. Missing data are described and not imputed.
Ethical considerations Participants not meeting eligibility criteria or requiring additional clinical care will be referred to appropriate healthcare services. The study is conducted in accordance with applicable ethical guidelines for human research.
80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.
This study's planned enrollment of 15 is below the median of 54 across 49 interventional studies indexed under Amenorrhea.
Browse Amenorrhea studies →Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 6, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women aged 18-40 years with functional hypothalamic amenorrhea (hypogonadotropic hypogonadism) verified by a gynecologist; able to read and understand Swedish; access to an internet-enabled device and BankID; written .
Exclusion Criteria:
Current anorexia nervosa, bulimia nervosa or binge-eating disorder according to the DIAMOND structured diagnostic interview (other specified feeding or eating disorder is not an exclusion criterion); severe psychiatric comorbidity requiring other or more intensive care, including psychosis; insufficient Swedish proficiency; other causes of amenorrhea, including pregnancy, thyroid disease, hyperprolactinemia and polycystic ovary syndrome.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will complete a 10-week web-based psychoeducational intervention for functional hypothalamic amenorrhea, with assessments at baseline, post-treatment, and 4-week follow-up.
Behavioral: 10-week web-based psychoeducational program
The intervention is a 10-week, self-guided, web-based psychoeducational program targeting biopsychosocial mechanisms underlying functional hypothalamic amenorrhea, including stress, energy availability, and exercise-related behaviors. Content was developed by a multidisciplinary clinical team in collaboration with patient representatives.
Participant satisfaction
1. Recruitment: number screened, eligible and enrolled, and proportion of eligible women who consent \[Time frame: October 2026-March 2027\]. 2. Retention: proportion of enrolled participants completing the 4-month assessment \[4 months\]. 3. Adherence: number of modules completed and proportion completing at least 5 of 10 modules (platform log data) \[10 weeks\]. 4. Treatment satisfaction: Client Satisfaction Questionnaire (CSQ-8) \[3 months\].
Time frame: Post-treatment (10 weeks)
1. Recruitment rate 2. Retention rate 3. Intervention completion rate 4. Perceived usefulness of intervention
1. Proportion of eligible participants who consent to participate in the study. (Unit of Measure: percentage of eligible participants) 2. Proportion of participants completing post-treatment assessment at 10 weeks. (Unit of Measure: percentage of enrolled participants) 3. Proportion of participants completing all 10 modules of the web-based program. (Unit of Measure: percentage of enrolled participants) 4. Participant-rated perceived usefulness of the program assessed post-treatment using a standardized rating scale. (Unit of Measure: scale score) 5 . Treatment credibility \[3 weeks\]. 5. Negative effects: Negative Effects Questionnaire (NEQ-20) \[3 months\].
Time frame: From enrollment to the end of study after 4 months
Psychiatric co-morbidity
EDE-Q, PSS-14, GAD-7, PHQ-9, WHO-5, ISI, IPAQ and FSFI-6 \[baseline and 4 months\]; psychiatric diagnoses according to DIAMOND \[baseline\].
Time frame: At enrollment and at study end
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Jul 2027, 8 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Jan 2026 → Nov 2026, primary completion Dec 2026 → Jul 2027 and completion Dec 2026 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.